# Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Canonical URL: https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-list-004ea5d8
Ticker: MDGL
Company: Madrigal
Source: Madrigal
Published: 2026-07-21 20:05 EST
## Summary

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering...

## Article Body
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on July 15, 2026 to ten new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, options to purchase 4,770 shares of Madrigal’s common stock, 7,433 time-based restricted stock units and 1,908 performance-based restricted stock units. Options have an exercise price of $550.25 per share, which is equal to the closing price of the company’s common stock on the grant date. Options vest as follows: (i) 25% of the option shares will vest on the first anniversary of the grant date and (ii) 6.25% of the option shares will vest on each quarterly anniversary following the first anniversary of the grant date. All restricted stock units granted vest in four equal installments on each of the first through fourth anniversaries of the grant date. Performance-based restricted stock units are earned based on the total shareholder return of Madrigal relative to a defined peer group over a three year period and, to the extent earned, will cliff vest in the first quarter of 2029. The vesting of all awards described above shall be subject to each such employee’s continued employment as of the applicable vesting date.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com .

Investor Contact Tina Ventura, IR@madrigalpharma.com

Media Contact Christopher Frates, media@madrigalpharma.com
## Recent Company News
- 2026-07-21 20:05 EST — [Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-list-004ea5d8) — Source: Madrigal
- 2026-07-16 12:00 EST — [Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026](https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-to-release-second-quarter-2026-financial-results-and-ho-8492a4a5) — Source: Madrigal
- 2026-07-13 12:00 EST — [Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio](https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-announces-three-new-resmetirom-patents-strengthening-ip-f27ea704) — Source: Madrigal
- 2026-07-06 20:05 EST — [Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-list-cb20d3fa) — Source: Madrigal
- 2026-06-22 20:05 EST — [Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-list-bbbe1357) — Source: Madrigal
## Related News
- 2026-07-27 15:00 EST — CAPR — [Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel](https://biopharmsignal.com/news/CAPR/capricor-comments-on-briefing-materials-ahead-of-july-29-fda-advisory-committee--3a3054d7)
- 2026-07-27 14:55 EST — GSK — [ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV](https://biopharmsignal.com/news/GSK/viiv-healthcare-s-2-drug-regimen-dovato-is-as-effective-as-3-drug-regimen-biktar-781cde81)
- 2026-07-27 13:00 EST — SPRO — [Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer](https://biopharmsignal.com/news/SPRO/spero-therapeutics-appoints-debra-jeske-zack-m-d-ph-d-as-chief-medical-officer-81a269de)
- 2026-07-27 12:32 EST — ICCM — [IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site](https://biopharmsignal.com/news/ICCM/icecure-medical-kicks-off-its-post-marketing-choice-study-for-the-low-risk-breas-9de814e1)
- 2026-07-27 12:10 EST — VERU — [Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss](https://biopharmsignal.com/news/VERU/veru-announces-full-enrollment-for-phase-2b-plateau-clinical-trial-of-enobosarm--ce89119d)